Surging Sales of US Biotech, CEO Sells 80,000 Shares and Plans 700 Billion Won Stock Buyback

BridgeBio Pharma, Inc. (Nasdaq: BBIO), a rare disease–focused biotech listed on Nasdaq, posted first-quarter 2026 revenues of $194.5 million, driven by expanded sales of its ATTR-CM therapy Attruby, while registering a net loss of $164 million. As of March 31, the company held $940 million in cash, cash equivalents and marketable securities. On May 6, its board approved a share repurchase program of up to $500 million. Earlier, on April 9–10, CEO Neil Kumar sold approximately 80,000 shares held in a trust under a Rule 10b5-1 plan for inheritance and asset management purposes, generating $5.97 million in cash; he continues to hold millions of shares directly and indirectly.

In early May, Brazil’s health regulatory authority ANVISA approved the commercial launch of acoramidis, marketed as BEYONTTRA, for adult ATTR-CM patients in Brazil, according to company announcements reported by global news and investment outlets. BridgeBio’s shares trade under the ticker BBIO; the company is classified as a mid-cap biotech dedicated to developing therapies for rare genetic and metabolic diseases.

Headquartered in California, BridgeBio Pharma develops and commercializes novel therapies targeting genetic and rare diseases. Its core products include the ATTR-CM treatment Attruby/BEYONTTRA and the pediatric rare metabolic disease therapy Nulibry. Founded in 2015 and listed on Nasdaq in 2019, the company’s pipeline features multiple clinical programs for rare skeletal and endocrine disorders, including LGMD2I/R9, ADH1 and achondroplasia.